))
#047 $CYTK’s Approval Delay The Biotech Oversight That Rocked Investors
Manage episode 509487166 series 3678700
Content provided by SueWallSt. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SueWallSt or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Did $CYTK gamble with the FDA and lose investor trust? In this episode of Sue Wall Street, we unpack the class action lawsuit against Cytokinetics Inc. Despite strong Phase 3 results, the company skipped a critical REMS in their NDA, delaying drug approval and tanking their stock. If you're into biotech moves, FDA filings, or securities law drama, this deep dive is for you. Learn how one missing document may cost shareholders millions.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
58 episodes
Share
